Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro

Cancer Cell International

Volumn 11, Issue , 2011, Pages

  Hoffmann, Katrin ^a   Xiao, Zhi ^a   Franz, Clemens ^a   Mohr, Elvira ^a   Serba, Susanne ^a   Büchler, Markus W ^a   Schemmer, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GEFITINIB; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CYTOSTASIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; UPREGULATION;

EID: 81155138333     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-11-40     Document Type: Article

References (33)

1. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002, 36:S74-S83.
2. Llovet JM, Bruix J. Hepatocellular carcinoma. The Lancet 2003, 362:1907-1917.
3. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:4293-4300. 10.1200/JCO.2005.01.3441, 16908937.
4. Ganne-Carrie N, Trinchet JC. Systemic treatment of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology 2004, 16:275-281.
5. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002, 53:615-627. 10.1146/annurev.med.53.082901.103929, 11818492.
6. Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 2001, 94:492-499. 10.1002/ijc.1498, 11745434.
7. Li B, Ye T, Zhao L, Li DH, Gou XH, Zhao LY, et al. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int 2006, 5:552-559.
8. Soini Y, Virkajarvi N, Raunio H, Paako P. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 1996, 49:470-473. 10.1136/jcp.49.6.470, 500536, 8763260.
9. Kato A, Miyazaki M, Ambiru S, Yoshitomi H, Ito H, Nakagawa K, et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001, 78:110-115. 10.1002/jso.1129, 11579388.
10. Vander BS, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 2008, 28:1370-1380. 10.1111/j.1478-3231.2008.01889.x, 19055643.
11. Barancik M, Bohacova V, Kvackajova J, Hudecova S, Krizanova O, Breier A. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 2001, 14:29-36. 10.1016/S0928-0987(01)00139-7, 11457647.
12. Yang JM, Sullivan GF, Hait WN. Regulation of the function of P-glycoprotein by epidermal growth factor through phospholipase C. Biochem Pharmacol 1997, 53:1597-1604. 10.1016/S0006-2952(97)82451-3, 9264311.
13. Yang JM, Vassil AD, Hait WN. Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway. Mol Pharmacol 2001, 60:674-680.
14. Kuo TC, Lu HP, Chao CC. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochem Pharmacol 2011, 82(2):184-94. 10.1016/j.bcp.2011.04.008, 21549688.
15. Guan J, Chen XP, Zhu H, Luo SF, Cao B, Ding L. Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. World J Gastroenterol 2004, 10:3522-3527.
16. Garcia R, Franklin RA, McCubrey JA. EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 2006, 5:2820-2826. 10.4161/cc.5.23.3535, 17172846.
17. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 1982, 42:3858-3863.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
19. Huet S, Marie JP, Gualde N, Robert J. Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network. Cytometry 1998, 34:248-256. 10.1002/(SICI)1097-0320(19981215)34:6<248::AID-CYTO2>3.0.CO;2-X, 9879641.
20. Herr I, Schemmer P, Buchler MW. On the TRAIL to therapeutic intervention in liver disease. Hepatology 2007, 46:266-274.
21. Herr I, Groth A, Schemmer P, Buchler MW. Adult stem cells in progression and therapy of hepatocellular carcinoma. Int J Cancer 2007, 121:1875-1882. 10.1002/ijc.23041, 17685426.
22. Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005, 12:364-373. 10.1245/ASO.2005.06.004, 15915370.
23. Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 2000, 275:39435-39443. 10.1074/jbc.M004583200, 10993883.
24. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004, 65:1485-1495. 10.1124/mol.65.6.1485, 15155841.
25. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J, Sugimoto Y. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 2007, 6:2092-2102. 10.1158/1535-7163.MCT-07-0148, 17620438.
26. Hirsch-Ernst KI, Ziemann C, Schmitz-Salue C, Foth H, Kahl GF. Modulation of P-glycoprotein and mdr1b mRNA expression by growth factors in primary rat hepatocyte culture. Biochem Biophys Res Commun 1995, 215:179-185. 10.1006/bbrc.1995.2450, 7575588.
27. Dickstein B, Valverius EM, Wosikowski K, Saceda M, Pearson JW, Martin MB, et al. Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J Cell Physiol 1993, 157:110-118. 10.1002/jcp.1041570115, 8408230.
28. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992, 255:459-462. 10.1126/science.1346476, 1346476.
29. Meyers MB, Shen WP, Spengler BA, Ciccarone V, O'Brien JP, Donner DB, et al. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 1988, 38:87-97. 10.1002/jcb.240380203, 2464605.
30. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, et al. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 2005, 65:6943-6949. 10.1158/0008-5472.CAN-05-0641, 16061679.
31. Gaikwad A, Wolf JK, Brown J, Ramondetta LM, Smith JA. In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines. J Oncol Pharm Practice 2009, 15:35-44.
32. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004, 22:777-784. 10.1200/JCO.2004.08.001, 14990632.
33. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004, 22:785-794. 10.1200/JCO.2004.07.215, 14990633.